Yuan H, Yao B, Li J T, Zhu W L, Ren D L, Wang H, Ma T H, Chen S Q, Wu J J, Tao Y R, Ye L, Wang Z Y, Qu H, Ma B, Zhong W W, Wang D J, Qiu J G
Department of Urology, the Sixth Affiliated Hospital, Sun Yat-sen University,Guangzhou 510655, China.
Department of Pelvic Floor Diseases, the Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510655, China.
Zhonghua Wei Chang Wai Ke Za Zhi. 2023 Mar 25;26(3):260-267. doi: 10.3760/cma.j.cn441530-20221024-00428.
To investigate the surgical indications and perioperative clinical outcomes of pelvic exenteration (PE) for locally advanced, recurrent pelvic malignancies and complex pelvic fistulas. This was a descriptive study.The indications for performing PE were: (1) locally advanced, recurrent pelvic malignancy or complex pelvic fistula diagnosed preoperatively by imaging and pathological examination of a biopsy; (2)preoperative agreement by a multi-disciplinary team that non-surgical and conventional surgical treatment had failed and PE was required; and (3) findings on intraoperative exploration confirming this conclusion.Contraindications to this surgical procedure comprised cardiac and respiratory dysfunction, poor nutritional status,and mental state too poor to tolerate the procedure.Clinical data of 141 patients who met the above criteria, had undergone PE in the Sixth Affiliated Hospital of Sun Yat-sen University from January 2018 to September 2022, had complete perioperative clinical data, and had given written informed consent to the procedure were collected,and the operation,relevant perioperative variables, postoperative pathological findings (curative resection), and early postoperative complications were analyzed. Of the 141 included patients, 43 (30.5%) had primary malignancies, 61 (43.3%) recurrent malignancies, 28 (19.9%) complex fistulas after radical resection of malignancies,and nine (6.4%)complex fistulas caused by benign disease. There were 79 cases (56.0%) of gastrointestinal tumors, 30 cases (21.3%) of reproductive tumors, 16 cases (11.3%) of urinary tumors, and 7 cases (5.0%) of other tumors such mesenchymal tissue tumors. Among the 104 patients with primary and recurrent malignancies, 15 patients with severe complications of pelvic perineum of advanced tumors were planned to undergo palliative PE surgery for symptom relief after preoperative assessment of multidisciplinary team; the other 89 patients were evaluated for radical PE surgery. All surgeries were successfully completed. Total PE was performed on 73 patients (51.8%),anterior PE on 22 (15.6%),and posterior PE in 46 (32.6%). The median operative time was 576 (453,679) minutes, median intraoperative blood loss 500 (200, 1 200) ml, and median hospital stay 17 (13.0,30.5)days.There were no intraoperative deaths. Of the 89 patients evaluated for radical PE surgery, the radical R0 resection was achieved in 64 (71.9%) of them, R1 resection in 23 (25.8%), and R2 resection in two (2.2%). One or more postoperative complications occurred in 85 cases (60.3%), 32 (22.7%)of which were Clavien-Dindo grade III and above.One patient (0.7%)died during the perioperative period. PE is a valid option for treating locally advanced or recurrent pelvic malignancies and complex pelvic fistulas.
探讨盆腔廓清术(PE)治疗局部晚期、复发性盆腔恶性肿瘤及复杂性盆腔瘘的手术适应证及围手术期临床结局。这是一项描述性研究。实施PE的适应证为:(1)术前经影像学检查及活检病理检查确诊为局部晚期、复发性盆腔恶性肿瘤或复杂性盆腔瘘;(2)多学科团队术前达成共识,非手术及传统手术治疗失败,需要行PE;(3)术中探查结果证实该结论。该手术的禁忌证包括心脏和呼吸功能障碍、营养状况差以及精神状态太差无法耐受手术。收集了2018年1月至2022年9月在中山大学附属第六医院接受PE且符合上述标准、围手术期临床资料完整并签署手术知情同意书的141例患者的临床资料,分析手术情况、相关围手术期变量、术后病理结果(根治性切除)及术后早期并发症。141例纳入患者中,43例(30.5%)为原发性恶性肿瘤,61例(43.3%)为复发性恶性肿瘤,28例(19.9%)为恶性肿瘤根治性切除术后的复杂性瘘,9例(6.4%)为良性疾病所致复杂性瘘。胃肠道肿瘤79例(56.0%),生殖系统肿瘤30例(21.3%),泌尿系统肿瘤16例(11.3%),其他肿瘤如间叶组织肿瘤7例(5.0%)。104例原发性和复发性恶性肿瘤患者中,15例晚期肿瘤盆腔会阴严重并发症患者经多学科团队术前评估后计划行姑息性PE手术以缓解症状;其余89例患者评估行根治性PE手术。所有手术均成功完成。73例(51.8%)患者行全盆腔廓清术,22例(15.6%)行前盆腔廓清术,46例(32.6%)行后盆腔廓清术。中位手术时间为576(453,679)分钟,中位术中出血量为500(200,1200)ml,中位住院时间为17(13.0,30.5)天。术中无死亡病例。89例评估行根治性PE手术的患者中,64例(71.9%)实现了根治性R0切除,23例(25.8%)为R1切除,2例(2.2%)为R2切除。85例(60.3%)患者发生1种或多种术后并发症,其中32例(22.7%)为Clavien-DindoⅢ级及以上。1例患者(0.7%)围手术期死亡。PE是治疗局部晚期或复发性盆腔恶性肿瘤及复杂性盆腔瘘的有效选择。